Cobimetinib Plus Atezolizumab for RAS and NF1/2-mutated Poorly Differentiated Thyroid Carcinoma.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined